Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2020

Qian Ling, Chen Kun, Wang Changhong, Chen Zhen, Meng Zhiqiang, Wang Peng

Abstract excerpt

PURPOSE: Oncogenic mutations in NRAS promote tumorigenesis. Although novel anti-NRAS inhibitors are urgently needed for the treatment of cancer, the protein is generally considered "undruggable" and no effective therapies have yet reached the clinic. STK19 kinase was recently reported to be a novel activator of NRAS and a potential therapeutic target for NRAS-mutant melanomas. Here, we describe a new...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Neoplasms

Share to Nuclear Proteins

Share to Protein Kinase Inhibitors

Share to Protein Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 32156748
DOI: 10.1158/1078-0432.CCR-19-2604

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine.PMID 32156748Read ↗

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.Semantic proximity Read ↗

Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma.Semantic proximity Read ↗

Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma.Semantic proximity Read ↗

Inhibition and degradation of NRAS with a pan-NRAS monobody.Semantic proximity Read ↗

Systematic analysis uncovers SYK dependency in NF1 <sup>LoF</sup> melanoma cellsSemantic proximity Read ↗

Reactivating cGAS-STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors.Semantic proximity Read ↗

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsSemantic proximity Read ↗

NRAS mutant melanoma--undrugable?Semantic proximity Read ↗

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid.Semantic proximity Read ↗

Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.Semantic proximity Read ↗

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.